MCRB Seres Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MCRB

Price (delayed)

$3.79

Market cap

$37.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.44

Enterprise value

$76.48M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the ...

Highlights
MCRB's revenue has surged by 64% since the previous quarter
Seres Therapeutics's gross profit has surged by 64% QoQ
Seres Therapeutics's net income has plunged by 126% YoY but it has soared by 52% from the previous quarter
The EPS has shrunk by 122% YoY but it has soared by 53% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.serestherapeutics.com
Peers: AGIO XNCR BIIB RGEN

Key stats

What are the main financial stats of MCRB

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
-5.72%
1 week
-9.98%
1 month
-16.89%
1 year
-78.42%
YTD
-74.53%
QTD
-51.96%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$1.88M
Gross profit
$1.88M
Operating income
-$84.03M
Net income
-$22.46M
Gross margin
100%
Net margin
-1,192.9%
Seres Therapeutics's net income has plunged by 126% YoY but it has soared by 52% from the previous quarter
MCRB's net margin has surged by 71% since the previous quarter
MCRB's revenue has surged by 64% since the previous quarter
Seres Therapeutics's gross profit has surged by 64% QoQ

Price vs fundamentals

How does MCRB's price correlate with its fundamentals

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
1.06
P/S
19.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.62
The EPS has shrunk by 122% YoY but it has soared by 53% QoQ
The price to book (P/B) is 64% lower than the last 4 quarters average of 3.1
The equity has increased by 30% QoQ and by 4.8% YoY
The stock's price to sales (P/S) is 89% less than its last 4 quarters average of 190.5
MCRB's revenue has surged by 64% since the previous quarter

Efficiency

How efficient is Seres Therapeutics business performance
The company's return on assets has shrunk by 133% YoY but it rose by 48% QoQ
The return on invested capital has dropped by 127% year-on-year but it has grown by 50% since the previous quarter
Seres Therapeutics's ROE has plunged by 121% YoY but it has soared by 53% from the previous quarter
The ROS has soared by 71% QoQ

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 52% higher than the total liabilities
The total liabilities has contracted by 40% YoY and by 26% from the previous quarter
MCRB's current ratio is up by 34% YoY and by 28% QoQ
MCRB's debt is 64% greater than its equity
Seres Therapeutics's debt to equity has decreased by 46% QoQ and by 38% YoY
MCRB's debt is down by 35% year-on-year and by 30% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.